Dexmedetomidine for sedation during electroencephalographic analysis in children with autism, pervasive developmental
Theresa Ray1, Joseph D Tobias2
1University of Missouri School of Medicine, Columbia, MO.
Insights
Dexmedetomidine effectively sedated children with autism or PDD for EEG tests. This medication proved safe and successful for pediatric procedural sedation, ensuring accurate electroencephalogram results.
Area of Science:
- Pediatric Neurology
- Anesthesiology
- Developmental Pediatrics
Background:
- Electroencephalogram (EEG) analysis is crucial for diagnosing neurological conditions in children.
- Sedation is often required for pediatric EEG to ensure patient cooperation and data quality.
- Children with autism spectrum disorder (ASD) and pervasive developmental disorders (PDDs) may present unique challenges for procedural sedation.
Purpose of the Study:
- To evaluate the efficacy and safety of dexmedetomidine for sedation during EEG analysis in pediatric patients.
- To assess dexmedetomidine's effectiveness in children diagnosed with autism, seizure disorders, or PDDs.
- To determine optimal dosing and administration routes for dexmedetomidine in this specific pediatric population.
Main Methods:
- Retrospective chart review of 42 children (aged 2-11 years) undergoing EEG with dexmedetomidine sedation.
- Data collection included dexmedetomidine administration route (oral/intravenous), dosage, and infusion rates.
- Monitoring of vital signs (heart rate, blood pressure, respiratory rate, oxygen saturation) and sedation levels throughout the procedure.
Main Results:
- Effective sedation was achieved in all pediatric patients.
- Dexmedetomidine was administered orally and/or intravenously, with adjustments to infusion rates and bolus doses as needed.
- No significant adverse hemodynamic or respiratory events were observed during the EEG procedures.
Conclusions:
- Dexmedetomidine is an effective and safe sedative agent for pediatric EEG analysis.
- The medication facilitates successful electroencephalogram acquisition in children with autism and PDDs.
- Dexmedetomidine offers a viable option for procedural sedation in challenging pediatric populations.
Study Objective:
To assess the efficacy of dexmedetomidine in providing sedation during electroencephalographic (EEG) analysis in children with autism, seizure disorders, or pervasive developmental disorders (PDDs).
Design:
Retrospective chart review.
Setting:
University medical center.
Measurements:
The charts of 42 children, aged two to 11 years, who received dexmedetomidine for sedation during EEG analysis, were studied. Information collected included route of administration of dexmedetomidine (oral and/or intravenous [i.v.]), loading dose, and infusion rate. Heart rate, blood pressure, respiratory rate, and level of sedation were monitored every 5 minutes, and oxygen saturation was monitored continuously during the procedure. Interventions (administration of fluid or use of an anticholinergic agent) for hypotension or bradycardia were identified.
Main Results:
18 children received oral dexmedetomidine (range, 2.9-4.4 microg/kg) before placement of an i.v.. Forty patients received an i.v. loading dose of dexmedetomidine (2.1 +/- 0.8 microg/kg), which was given in increments of 0.5 to one microg/kg every three to 5 minutes until a sedation score of 3 to 4 was achieved. Effective sedation was eventually achieved in all patients. An i.v. infusion of dexmedetomidine was started (1.5 +/- 0.2 microg kg(-1) hr(-1)) in all patients. During performance of the EEG, adjustments in the infusion rate (increase or decrease) or additional bolus doses were necessary in 25 patients. No significant hemodynamic or respiratory effects were noted.
Conclusions:
Dexmedetomidine provides effective sedation during EEG analysis in children with autism or PDD.
Related Concept Videos
01:24Parenteral Anesthetics: Overview
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...